Mission Bio announced its expansion into single-cell multiomics. The company’s proprietary technology, the Tapestri Platform, is a single-cell multiomic platform capable of detecting DNA and protein changes simultaneously from the same cell — a capability necessary for the development of impactful precision therapies. The company has partnered with BioLegend, a global player in protein antibody and reagent manufacturing, to co-develop the first commercial solution for true multiomics at the single-cell level.
Through its extension into multiomics, a market projected to reach $5 billion by 2025, Mission Bio’s Tapestri Platform simultaneously detects single nucleotide variants (SNVs), copy number variations (CNVs) and proteins from the same cell. With access to multiple layers of the cellular profile, the Tapestri Platform provides the insight necessary to develop treatments that target the right set of biomarkers in diseased cells.
“Connecting the DNA mutational profile with the protein profile of the same cell is transforming our understanding of cancer, as this gives us the capability to connect somatic mutations to specific differentiation states, and to really understand how leukemia initiates and evolves. This is a game-changer when it comes to developing precise, effective treatments,” explained Ross Levine, MD, Chief of Molecular Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center, Human Oncology and Pathogenesis Program. “With this insight, we can see the past, present, and future of each person’s cancer, determine how it evolves, and develop new therapeutic approaches aimed to prevent disease evolution and relapse.”
Mission Bio’s Tapestri Single-Cell DNA Panels will enable SNV and CNV detection in combination with oligonucleotide-conjugated antibodies from BioLegend, providing dozens of protein targets and hundreds of DNA targets within a single panel for a revolutionary, integrated workflow.
“Our customers have a strong demand for a solution that pairs their current single-cell phenotype data with correlated genotypes from the very same cells,” said Gene Lay, CEO of BioLegend. “With Mission Bio as the leaders in single-cell DNA analysis, we are excited to co-develop the first truly single-cell multiomic solution to meet the research community’s growing needs.”
